Eledon Pharmaceuticals Inc Ordinary Shares ELDN 深 滬
已收盤 08-01 16:00:00 美东时间
3.38
+0.230
+7.30%
華盛通- 最 高3.43
- 今 開3.11
- 成交量 65.32万股
- 最 低 3.07
- 昨 收 3.15
- 總市值 2.02亿
- 52周最高 5.54
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.375
- 委 比 -14.63%
- 總股本 5988.18万
- 歷史最高 154.98
- 量 比 0.61
- 振 幅 11.43%
- 歷史最低 1.07
- 每 手 1
- 風險率 0.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅102.43%！Mobileye Global获Canaccord Genuity升目标价至30美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Mobileye Global"买入"评级，目标价从25美元升至30美元；巴克莱：维持TechnipFMC"超配"评级，目标价从45美元升至51美元
07-28 09:33
Craig-Hallum Initiates Coverage On Eledon Pharmaceuticals with Buy Rating, Announces Price Target of $12
Craig-Hallum initiates coverage on Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $12.
07-26 01:54
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals will present updated clinical data on tegoprubart for kidney transplantation at the World Transplant Congress in San Francisco on August 6, 2025. The presentation by Dr. John Gill from the University of British Columbia will include results from approximately 30 kidney transplant recipients. Additionally, preclinical data on tegoprubart for liver transplantation in non-human primates will be presented in a poster session. E...
07-17 20:01
Eledon And Sernova Collaborate To Test Tegoprubart As Safer Immunosuppressant In Sernova's Phase 1/2 Cell Pouch Trial For Type 1 Diabetes
Sernova Biotherapeutics ("Sernova") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) to evaluate Eledon's
07-09 20:36
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Eledon Pharmaceuticals will host an R&D Day on July 9, 2025, in New York City, featuring its executive team and leading transplantation experts. The event will focus on its investigational candidate, tegoprubart, particularly its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial. Sessions will address unmet needs in solid organ transplantation, evolution of clinical endpoints, and strategic opportu...
06-25 20:01
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
HC Wainwright & Co. Assumes Eledon Pharmaceuticals at Buy, Announces Price Target of $9
HC Wainwright & Co. analyst Yi Chen assumes Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy rating and announces Price Target of $9.
06-18 19:38
Eledon Pharma Q1 EPS $(0.08) Beats $(0.30) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.30) by 73.33 percent. This is a 89.87 percent increase over losses of $(0.79) per share from the
05-15 04:22
Eledon Pharma Adjusts CEO Bonus Structure
Eledon Pharmaceuticals ( ($ELDN) ) has issued an update. Eledon Pharmaceuticals...
2024-12-20 21:28
HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $16 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Eledon Pharma (NASDAQ:ELDN) with a Buy and maintains $16 price target.
2024-11-20 21:17
